SureNano Science Ltd. Acquires GlucaPharm Inc., Advancing Second-Generation FDA Pathway GLP-1 Drug Development

GlucaPharm is developing GEP44, a novel, patented peptide (similar in function to Ozempic®, Wegovy®, Mounjaro®, but with reduced risk of adverse events) discovered by researchers at Syracuse University.Vancouver, British Columbia--(Newsfile Corp. - February 23, 2026) - SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) ("SureNano" or the "Company") is pleased to announce that it has completed the acquisition of GlucaPharm Inc. ("GlucaPharm"), a next-generation glucagon-like peptide ("GLP") pharmaceutical com ...